Alto Neuroscience, Inc. (ANRO) intrinsic value & 10-year financials
Alto Neuroscience, Inc. (ANRO) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $21.94
- Market cap
- $633.0M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 694.4%
- Free cash flow (FY2025)
- -$51.8M
ANRO 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$63.2M | -$2.19 | -$51.8M | — | 1963.1% |
| FY2024 | — | -$61.4M | -$2.50 | -$49.5M | — | 93.8% |
| FY2023 | — | -$36.3M | -$9.73 | -$33.9M | — | 26.2% |
| FY2022 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Alto Neuroscience, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Alto Neuroscience, Inc. has earned high returns on invested capital, averaging 46.5% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Alto Neuroscience, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Alto Neuroscience, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.